Evidence map›Paper›PMID 35681696›Full record

ArticleCancers2022

Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial.

Stephanie Archer, Nichola Fennell, Ellen Colvin, Rozelle Laquindanum, Meredith Mills, Romy Dennis, Francisca Stutzin Donoso, Rochelle Gold, Alice Fan, Kate Downes and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Using Polygenic Risk Scores to Refine Risk and Outcomes in High-grade Serous Ovarian Cancer in Australia.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Polygenic scores in cancer.Nature reviews. Cancer · 2023
    Review
  8. Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Stephanie ArcherPrimary Care Unit, Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Cambridge CB1 8RN, UK.ORCID 0000-0003-1349-7178
Nichola FennellAcademic Department of Medical Genetics, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.ORCID 0000-0002-5711-6341
Ellen ColvinManchester Centre for Genomic Medicine, St. Marys Hospital, Oxford Road, Manchester M13 9WL, UK.
Rozelle LaquindanumDepartment of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Meredith MillsDepartment of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Romy DennisAcademic Department of Medical Genetics, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.
Francisca Stutzin DonosoPrimary Care Unit, Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Cambridge CB1 8RN, UK.ORCID 0000-0003-1590-1226
Rochelle GoldAcademic Department of Medical Genetics, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.
Alice FanDepartment of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-4813-5444
Kate DownesCambridge Genomics Laboratory, Cambridge University Hospitals Foundation Trust, Hills Road, Cambridge CB2 0QQ, UK.
James FordDepartment of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Antonis C AntoniouCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Cambridge CB1 8RN, UK.ORCID 0000-0001-9223-3116
Allison W KurianDepartment of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-6175-9470
D Gareth EvansManchester Centre for Genomic Medicine, St. Marys Hospital, Oxford Road, Manchester M13 9WL, UK.ORCID 0000-0002-8482-5784
Marc TischkowitzAcademic Department of Medical Genetics, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.ORCID 0000-0002-7880-0628
University of Cambridge · GBStanford University · USCambridge University Hospitals NHS Foundation Trust · GBManchester Academic Health Science Centre · GBSt Mary's Hospital · GB

Funding

Cancer Research UK 31523Cancer Research UK C22770/A31523
6 · The paper itself

Abstract

Women who test positive for an inherited pathogenic/likely pathogenic gene variant in

Indexed as

breast cancerCanRiskepithelial ovarian cancergeneticspersonalised risk predictionpolygenic risk scores

Identifiers

PMID35681696
PMCPMC9179465
OpenAlexW4281867377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.